Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

WALTHAM, Mass., March 27, 2024 -- Dyne Therapeutics, Inc. , a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically...

Related Keywords

Johng Cox ,Amy Reilly ,Linkedin ,Nasdaq ,Dyne Therapeutics Inc ,Facebook ,Compensation Committee Of Dyne ,Chief Executive Officer ,Compensation Committee ,Stock Incentive Plan ,Nasdaq Listing Rule ,Nasdaq Global Select Market ,Stock Incentive ,Markets ,